Clovis Oncology Inc expected to post a loss of 43  cents a share - Earnings Preview

Clovis Oncology

02/05/2022 19:31

* Clovis Oncology Inc  CLVS.OQ   CLVS.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 4. 
    * The Boulder Colorado-based  company is expected to report 
a
2.8% decrease in revenue to $36.976 million from $38.05 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Clovis Oncology Inc
is
for a loss of 43 cents per share. For the same quarter last
year, the company reported a loss of 64 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Clovis
Oncology
Inc is $4​, above​ its last closing price of $2.00. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.55       -0.57      -0.48     Beat    15.8
 Sep. 30 2021  -0.47       -0.48      -0.56     Missed  -17.2
 Jun. 30 2021  -0.55       -0.56      -0.61     Missed  -8​
 Mar. 31 2021  -0.73       -0.72      -0.64     Beat    10.9
 ​​Dec.        -0.76       -0.77      -1.02     Missed  -32.5
 31 2020                                                
 Sep. 30 2020  -0.98       -0.99      -0.89     Beat    10.3​
 Jun. 30 2020  -1.03       -1.04      -1.15     Missed  -10.1
 Mar. 31 2020  -1.24       -1.28      -1.28     Met     -0.1
 This summary was machine generated May 2 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated